Luckily, those two factors will neutralize each other.
Would it be the best thing that we spend money to have a vaccine for pandemic flu that never happened? ... That would be a great outcome as far as I'm concerned.
It selects the virus to try and escape from the drugs by becoming resistant. That's a natural thing that any microbe does when you treat it.
The older you get, the greater the probability that you would not only have serious complications, but you would actually die.
There are some states that are having now that kind of activity that we didn't see in October, November, December, which tells us what we already know -- that the season is not over. Certainly, the early part of the season was relatively light, much to our great advantage in light of the [vaccine] shortage.
What we learned from the mail-service anthrax attack of 2001 is that you really have to look at the vulnerable people along the chain of exposure.
It's a good start what the World Bank is doing.
There is good reason for excitement because it's finally going to answer the question whether or not a vaccine works.
The good news is this is highly effective in blocking smallpox in the laboratory and in a mouse model, ... But the sobering news is it's only been studied in the test tube and mouse model, so we shouldn't get too excited yet. Smallpox is an important disease that we need therapies for, so that's why we're looking at this with great interest.
short-term amelioration of the shortage response.
If you're going to allow people, even voluntarily, to get vaccinated, it's important that they truly understand, as best as you possibly can communicate to them, that there are risks associated with the vaccine.
With all of these drugs, some more than others, there's the development of resistance. So it's certainly not a cure, but it was a dramatic turnaround.
That's the thing that from the research standpoint we are working on very diligently right now, ... Of developing new types of approaches, of being able to quicken and give greater efficiency to the process of being able to identify the strain and getting it into the vaccine in time.
Most of the time, in the real world, you get a patient after they've been infected for a reasonably long period of time.
You have to play catch-up in development.